Facing Nasdaq Delisting, Hybridon Plans One-for-Five Reverse Stock Split | GenomeWeb

CAMBRIDGE, Mass.--Hybridon, a genetically based drug discovery company here, has filed with the US Securities and Exchange Commission for a one-for-five reverse stock split, which would shrink the company's outstanding shares from about 25 million to 5 million. The plan, which will be presented to shareholders at a special meeting November 18, was proposed to help the company continue to meet Nasdaq listing requirements.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.